NEW YORK (GenomeWeb) – Indi Molecular said today that it has entered into a co-development deal with Sigma-Aldrich to explore the use of Indi Molecular's PCC (protein catalyzed capture) agent technology in Sigma-Aldrich's line of biological reagents.
The project will analyze using the PCC agents, which are synthetic peptides capable of protein binding with similar performance to traditional antibodies and with potentially lower development times and costs, for protein research.
"Indi’s PCC technology is a promising technology that we believe may play an important role in designing cutting-edge biological tools," Patrick Sullivan, vice president, research & development at Sigma-Aldrich, said in a statement.
Indi Molecular, which was launched as a spinout from its parent company Integrated Diagnostics in 2013, also aims to develop the molecules as reagents for applications including in vivo imaging, in vitro diagnostics, and as therapeutics.
Financial and other terms of the agreement were not disclosed.